Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Profit After Tax (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Profit After Tax for 11 consecutive years, with -$92.6 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 802.92% to -$92.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$130.3 million through Dec 2025, down 68.3% year-over-year, with the annual reading at -$130.3 million for FY2025, 68.3% down from the prior year.
  • Profit After Tax for Q4 2025 was -$92.6 million at Cartesian Therapeutics, down from -$35.9 million in the prior quarter.
  • The five-year high for Profit After Tax was $28.8 million in Q1 2022, with the low at -$177.7 million in Q4 2023.
  • Average Profit After Tax over 5 years is -$20.9 million, with a median of -$10.8 million recorded in 2023.
  • The sharpest move saw Profit After Tax crashed 3114.73% in 2023, then soared 221.51% in 2024.
  • Over 5 years, Profit After Tax stood at $12.2 million in 2021, then plummeted by 51.85% to $5.9 million in 2022, then crashed by 3114.73% to -$177.7 million in 2023, then soared by 94.23% to -$10.3 million in 2024, then plummeted by 802.92% to -$92.6 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$92.6 million, -$35.9 million, and $15.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.